92 related articles for article (PubMed ID: 19037840)
1. BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors.
Minkovsky N; Berezov A
Curr Opin Investig Drugs; 2008 Dec; 9(12):1336-46. PubMed ID: 19037840
[TBL] [Abstract][Full Text] [Related]
2. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.
Solca F; Dahl G; Zoephel A; Bader G; Sanderson M; Klein C; Kraemer O; Himmelsbach F; Haaksma E; Adolf GR
J Pharmacol Exp Ther; 2012 Nov; 343(2):342-50. PubMed ID: 22888144
[TBL] [Abstract][Full Text] [Related]
3. Afatinib (BIBW 2992) development in non-small-cell lung cancer.
Hirsh V
Future Oncol; 2011 Jul; 7(7):817-25. PubMed ID: 21732753
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.
Yap TA; Vidal L; Adam J; Stephens P; Spicer J; Shaw H; Ang J; Temple G; Bell S; Shahidi M; Uttenreuther-Fischer M; Stopfer P; Futreal A; Calvert H; de Bono JS; Plummer R
J Clin Oncol; 2010 Sep; 28(25):3965-72. PubMed ID: 20679611
[TBL] [Abstract][Full Text] [Related]
5. Afatinib for the treatment of metastatic non-small cell lung cancer.
Joshi M; Rizvi SM; Belani CP
Cancer Manag Res; 2015; 7():75-82. PubMed ID: 25733926
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.
Lin NU; Winer EP; Wheatley D; Carey LA; Houston S; Mendelson D; Munster P; Frakes L; Kelly S; Garcia AA; Cleator S; Uttenreuther-Fischer M; Jones H; Wind S; Vinisko R; Hickish T
Breast Cancer Res Treat; 2012 Jun; 133(3):1057-65. PubMed ID: 22418700
[TBL] [Abstract][Full Text] [Related]
7. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.
De Grève J; Teugels E; Geers C; Decoster L; Galdermans D; De Mey J; Everaert H; Umelo I; In't Veld P; Schallier D
Lung Cancer; 2012 Apr; 76(1):123-7. PubMed ID: 22325357
[TBL] [Abstract][Full Text] [Related]
8. Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer.
Li W; Zhang K; Wang W; Liu Y; Huang J; Zheng M; Li L; Zhang X; Xu M; Chen G; Wang L; Zhang S
J Exp Clin Cancer Res; 2024 Feb; 43(1):56. PubMed ID: 38403634
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of Immune Checkpoints: Small Molecule- and Peptide-Based Approaches.
Fuchs N; Zhang L; Calvo-Barreiro L; Kuncewicz K; Gabr M
J Pers Med; 2024 Jan; 14(1):. PubMed ID: 38248769
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity.
Marret G; Temam S; Kamal M; Even C; Delord JP; Hoffmann C; Dolivet G; Malard O; Fayette J; Capitain O; Vergez S; Geoffrois L; Rolland F; Zrounba P; Laccourreye L; Saada-Bouzid E; Aide N; Bénavent V; Klijianenko J; Lamy C; Girard E; Vacher S; Masliah-Planchon J; de Koning L; Puard V; Borcoman E; Jimenez M; Bièche I; Gal J; Le Tourneau C
Sci Rep; 2023 Dec; 13(1):22524. PubMed ID: 38110561
[TBL] [Abstract][Full Text] [Related]
11. Developing a Mathematical Model of Intracellular Calcium Dynamics for Evaluating Combined Anticancer Effects of Afatinib and RP4010 in Esophageal Cancer.
Chang Y; Funk M; Roy S; Stephenson E; Choi S; Kojouharov HV; Chen B; Pan Z
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163685
[TBL] [Abstract][Full Text] [Related]
12. Current status and future perspectives in HER2 positive advanced gastric cancer.
Roviello G; Catalano M; Iannone LF; Marano L; Brugia M; Rossi G; Aprile G; Antonuzzo L
Clin Transl Oncol; 2022 Jun; 24(6):981-996. PubMed ID: 35091998
[TBL] [Abstract][Full Text] [Related]
13. Androgen Receptor Activation in Glioblastoma Can Be Achieved by Ligand-Independent Signaling through EGFR-A Potential Therapeutic Target.
Zalcman N; Gutreiman M; Shahar T; Weller M; Lavon I
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681618
[TBL] [Abstract][Full Text] [Related]
14. Exploring effects of DNA methylation and gene expression on pan-cancer drug response by mathematical models.
Lv W; Zhang X; Dong H; Wu Q; Sun B; Zhang Y
Exp Biol Med (Maywood); 2021 Jul; 246(14):1626-1642. PubMed ID: 33910405
[TBL] [Abstract][Full Text] [Related]
15. Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells.
You KS; Yi YW; Cho J; Seong YS
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33801977
[TBL] [Abstract][Full Text] [Related]
16. Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?
Roviello G; Aprile G; D'Angelo A; Iannone LF; Roviello F; Polom K; Mini E; Catalano M
Gastric Cancer; 2021 Jul; 24(4):765-779. PubMed ID: 33742317
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer.
Yang X; Wu D; Yuan S
Technol Cancer Res Treat; 2020; 19():1533033820962140. PubMed ID: 33034269
[TBL] [Abstract][Full Text] [Related]
18. The Emerging Therapeutic Potential of Nitro Fatty Acids and Other Michael Acceptor-Containing Drugs for the Treatment of Inflammation and Cancer.
Piesche M; Roos J; Kühn B; Fettel J; Hellmuth N; Brat C; Maucher IV; Awad O; Matrone C; Comerma Steffensen SG; Manolikakes G; Heinicke U; Zacharowski KD; Steinhilber D; Maier TJ
Front Pharmacol; 2020; 11():1297. PubMed ID: 33013366
[TBL] [Abstract][Full Text] [Related]
19. The ATF6-EGF Pathway Mediates the Awakening of Slow-Cycling Chemoresistant Cells and Tumor Recurrence by Stimulating Tumor Angiogenesis.
Cho J; Min HY; Pei H; Wei X; Sim JY; Park SH; Hwang SJ; Lee HJ; Hong S; Shin YK; Lee HY
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630838
[TBL] [Abstract][Full Text] [Related]
20. Concurrent inhibition of ErbB family and MEK/ERK kinases to suppress non-small cell lung cancer proliferation.
Lin X; Liao J; Geng X; Dan H; Chen L
Am J Transl Res; 2020; 12(3):847-856. PubMed ID: 32269717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
